AI Drug Discovery
AI-accelerated pharmaceutical research and clinical trial optimization.
Active institutional exposure flipped from a net outflow of $4.3 billion in Q1 2026 to a net inflow of $9.3 billion in Q2 2026. 60.9% of companies in this theme saw increased active positions in Q2 2026.
Ecosystem Map
AI platforms combining genomics, proteomics, phenotypic data or biological foundation models for target discovery. Excludes routine diagnostic testing without a computational-discovery platform.
AI-driven clinical-trial design, patient matching, real-world evidence and trial operations. Excludes CROs without material AI differentiation.
Companies using proprietary AI/ML platforms to identify or design therapeutic candidates. Includes hybrid platform-and-pipeline companies; excludes general research software without drug-discovery validation.
Bottleneck Tracker
Bottleneck details are part of the Pro plan.
Recent Discoveries
Recent discoveries are part of the Pro plan.